Instrument Inactif

Autres langues Endologix, Inc. Nasdaq

Actions

US29266S1069

Equipement, fournitures et distribution médicale

Autres langues

19/05	Endologix LLC acquired Pounce? Thrombectomy System from Surmodics, Inc.
07/05	Endologix LLC Announces Appointment of Steve Deitsch to Board of Directors
09/07/25	Endologix Announces That Scott Huennekens Joins Board of Directors
20/03/25	Endologix Announces 1000 Patients Treated with the Detour? System
03/03/25	Endologix LLC Appoints Andrew Davis as Chief Commercial Officer
07/01/25	Endologix LLC Announces Chief Executive Officer Changes
07/01/25	Endologix LLC Announces Executive Changes
05/11/24	Endologix LLC Announces 36-Month Results of Detour2 Study At 2024 Viva Late-Breaking Clinical Trial Session
18/06/24	Endologix LLC Appoints Graham Phillips as Chief Operating Officer
13/05/24	Endologix LLC Announces Online Publication of the One-Year Results of the DETOUR2 Trial in the Journal of Vascular Surgery
05/03/24	Endologix LLC Appoints Mike Mathias as Chief Commercial Officer
25/01/24	Endologix LLC Announces That Art Taylor Joins Board of Directors
09/01/24	Endologix LLC Appoints Scott Ward Joins Board of Directors
09/01/24	Endologix LLC Announces Appointment of Scott Ward as Board of Directors
27/12/23	Endologix LLC Announces the U. S. Centers for Medicare & Medicaid Services Grants Transitional Pass-Through Payment for the Detour System
02/11/23	Endologix Announces Results of Pooled Analysis of DETOUR1 and DETOUR2 Studies at 2023 VIVA Late-Breaking Clinical Trial Session
07/09/23	Endologix Llc Announces the U. S. Centers for Medicare & Medicaid Services Grants New Technology Add-On Payment for the Detour System
24/08/23	Endologix LLC Appoints Lucas Buchanan to its Board of Directors
18/07/23	Endologix Announces First Patients Treated with the DETOUR?? System, Advancing Treatment for Complex Peripheral Artery Disease
15/06/23	Endologix LLC Announces 24-Month Results of DETOUR-2 Study at 2023 Vascular Annual Meeting
08/06/23	Endologix Llc Receives Fda Approval of the Detour System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with Pad
23/05/23	Endologix LLC Announces 150Th Patient Enrolled in JAGUAR Randomized Controlled Trial
11/11/22	Endologix Announces 12-Month Results of DETOUR-2 Trial at 2022 VIVA Late-Breaking Clinical Trial Session
03/11/22	Endologix LLC Announced the Five-Year Results from the Leopard Randomized Controlled Trial
20/10/22	Endologix LLC Announces the Elevate